Does Rallies show 13F holders for ERAS?

Yes. Rallies tracks hedge fund and 13F ownership data for ERAS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ERAS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ERAS. It does not provide personalized investment advice.

ERAS (Erasca, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Erasca, Inc. Common Stock (ERAS) is a publicly traded Healthcare sector company. As of May 21, 2026, ERAS trades at $11.09 with a market cap of $3.19B and a P/E ratio of -25.11. ERAS moved +7.95% today. Year to date, ERAS is +218.63%; over the trailing twelve months it is +768.75%. Its 52-week range spans $1.01 to $24.28. Analyst consensus is buy with an average price target of $20.27. Rallies surfaces ERAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ERAS stock?

Hedge funds tracked by Rallies that own ERAS include Panagora Asset and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Erasca, Inc. Common Stock.

ERAS Key Metrics

Key financial metrics for ERAS
Metric	Value
Price	$11.09
Market Cap	$3.19B
P/E Ratio	-25.11
EPS	$-0.44
Dividend Yield	0.00%
52-Week High	$24.28
52-Week Low	$1.01
Volume	5.83M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-124.55M
Gross Margin	0.00%

Top Hedge Funds Holding ERAS

Panagora Asset holds 118.22K shares of ERAS, changed +15.47% as of Dec 31, 2025.
Farallon Capital holds 18.00K shares of ERAS, changed +0.00% as of Mar 31, 2026.

Latest ERAS News

Erasca Bolsters Cash to $408.5M, Highlights ERAS-0015 NSCLC and PDAC Responses — May 11, 2026
Erasca Strikes Merck Pact to Combine ERAS-0015 with Keytruda in Phase 1 Trial — May 11, 2026
Erasca slides 5% after ERAS-0015 update pushes key readouts into 2027 — Apr 29, 2026
Erasca Shares Plunge 46% After Trial Death Despite 62% NSCLC Response — Apr 29, 2026
Erasca plunges 43% after ERAS-0015 trial patient death sparks safety fears — Apr 28, 2026

Recent ERAS Insider Trades

Garner Ebun sold 80.00K (~$1.31M) on Apr 1, 2026.
Morris Shannon sold 20.00K (~$300.76K) on Mar 4, 2026.
Garner Ebun sold 120.00K (~$670.81K) on Jan 7, 2026.

ERAS Analyst Consensus

11 analysts cover ERAS: 0 strong buy, 9 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.27.

Common questions about ERAS

Who owns ERAS stock?: Hedge funds tracked by Rallies that own ERAS include Panagora Asset and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Erasca, Inc. Common Stock.
Does Rallies show 13F holders for ERAS?: Yes. Rallies tracks hedge fund and 13F ownership data for ERAS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ERAS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ERAS. It does not provide personalized investment advice.